NeoGenomics falls after Q1 sales miss

NeoGenomics

29/04/2025 13:54

** Cancer testing services firm NeoGenomics' NEO.O shares fall 3.6% to $9.61 premarket

     ** Company reports Q1 revenue of $168 million, missing analysts' estimates of $171 million, according to data compiled by LSEG

** But company raises its annual revenue forecast to be between $747 million and $759 million, up from previous range of $735 million to $745 million

** Separately, company says it is collaborating with biotech firm Ultima Genomics to expand clinical test offerings for cancer patients using Ultima's sequencing platform designed for large-scale genomic studies

** As of last close, NEO has fallen 39.5% YTD

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))